TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors

Neil Senzer, Sridhar Mani, Alexander Rosemurgy, John Nemunaitis, Casey Cunningham, Chandan Guha, Natalia Bayol, Michelle Gillen, Karen Chu, Camilla Rasmussen, Henrik Rasmussen, Donald Kufe, Ralph Weichselbaum, Nader Hanna

Research output: Contribution to journalArticle

173 Citations (Scopus)

Abstract

Purpose: TNFerade is a replication deficient adenovector that expresses human tumor necrosis factor alpha under control of the radiation-inducible Egr-1 promoter. The goals of this study were to determine the safety and toxicity of TNFerade in combination with radiation therapy. Patients and Methods: TNFerade was administered by intratumoral administration, weekly for 6 weeks with concomitant radiation (30 to 70 Gy). Seven dose levels were studied (4 × 107 particle units [pu] to 4 × 1011 pu) in patients with solid tumors being treated with radiation. Results: Thirty-six patients were assessable for toxicity and 30 for tumor response. Most frequent TNFerade-related toxicities were fever (22%), injection site pain (19%), and chills (19%). No dose-limiting toxicities were observed. Overall, 21 of 30 patients (70%) demonstrated objective tumor response (five complete responses, nine partial responses, and seven minimal responses). In four of five patients with synchronous lesions, a differential response between lesions treated with TNFerade + radiation compared with radiation only was observed. Conclusion: This is the first human study with TNFerade and radiation. The integrated treatment was well tolerated in patients with predominantly prior treatment-refractory solid tumors. Controlled prospective clinical trials have been initiated to more fully define the therapeutic contribution of TNFerade.

Original languageEnglish (US)
Pages (from-to)592-601
Number of pages10
JournalJournal of Clinical Oncology
Volume22
Issue number4
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

Tumor Necrosis Factor-alpha
Radiation
Genes
Neoplasms
Chills
Controlled Clinical Trials
human TNF protein
Fever
Radiotherapy
Therapeutics
Safety
Pain
Injections

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene : A phase I study in patients with solid tumors. / Senzer, Neil; Mani, Sridhar; Rosemurgy, Alexander; Nemunaitis, John; Cunningham, Casey; Guha, Chandan; Bayol, Natalia; Gillen, Michelle; Chu, Karen; Rasmussen, Camilla; Rasmussen, Henrik; Kufe, Donald; Weichselbaum, Ralph; Hanna, Nader.

In: Journal of Clinical Oncology, Vol. 22, No. 4, 2004, p. 592-601.

Research output: Contribution to journalArticle

Senzer, N, Mani, S, Rosemurgy, A, Nemunaitis, J, Cunningham, C, Guha, C, Bayol, N, Gillen, M, Chu, K, Rasmussen, C, Rasmussen, H, Kufe, D, Weichselbaum, R & Hanna, N 2004, 'TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors', Journal of Clinical Oncology, vol. 22, no. 4, pp. 592-601. https://doi.org/10.1200/JCO.2004.01.227
Senzer, Neil ; Mani, Sridhar ; Rosemurgy, Alexander ; Nemunaitis, John ; Cunningham, Casey ; Guha, Chandan ; Bayol, Natalia ; Gillen, Michelle ; Chu, Karen ; Rasmussen, Camilla ; Rasmussen, Henrik ; Kufe, Donald ; Weichselbaum, Ralph ; Hanna, Nader. / TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene : A phase I study in patients with solid tumors. In: Journal of Clinical Oncology. 2004 ; Vol. 22, No. 4. pp. 592-601.
@article{d05de9996df440c79ea68e4372301573,
title = "TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors",
abstract = "Purpose: TNFerade is a replication deficient adenovector that expresses human tumor necrosis factor alpha under control of the radiation-inducible Egr-1 promoter. The goals of this study were to determine the safety and toxicity of TNFerade in combination with radiation therapy. Patients and Methods: TNFerade was administered by intratumoral administration, weekly for 6 weeks with concomitant radiation (30 to 70 Gy). Seven dose levels were studied (4 × 107 particle units [pu] to 4 × 1011 pu) in patients with solid tumors being treated with radiation. Results: Thirty-six patients were assessable for toxicity and 30 for tumor response. Most frequent TNFerade-related toxicities were fever (22{\%}), injection site pain (19{\%}), and chills (19{\%}). No dose-limiting toxicities were observed. Overall, 21 of 30 patients (70{\%}) demonstrated objective tumor response (five complete responses, nine partial responses, and seven minimal responses). In four of five patients with synchronous lesions, a differential response between lesions treated with TNFerade + radiation compared with radiation only was observed. Conclusion: This is the first human study with TNFerade and radiation. The integrated treatment was well tolerated in patients with predominantly prior treatment-refractory solid tumors. Controlled prospective clinical trials have been initiated to more fully define the therapeutic contribution of TNFerade.",
author = "Neil Senzer and Sridhar Mani and Alexander Rosemurgy and John Nemunaitis and Casey Cunningham and Chandan Guha and Natalia Bayol and Michelle Gillen and Karen Chu and Camilla Rasmussen and Henrik Rasmussen and Donald Kufe and Ralph Weichselbaum and Nader Hanna",
year = "2004",
doi = "10.1200/JCO.2004.01.227",
language = "English (US)",
volume = "22",
pages = "592--601",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene

T2 - A phase I study in patients with solid tumors

AU - Senzer, Neil

AU - Mani, Sridhar

AU - Rosemurgy, Alexander

AU - Nemunaitis, John

AU - Cunningham, Casey

AU - Guha, Chandan

AU - Bayol, Natalia

AU - Gillen, Michelle

AU - Chu, Karen

AU - Rasmussen, Camilla

AU - Rasmussen, Henrik

AU - Kufe, Donald

AU - Weichselbaum, Ralph

AU - Hanna, Nader

PY - 2004

Y1 - 2004

N2 - Purpose: TNFerade is a replication deficient adenovector that expresses human tumor necrosis factor alpha under control of the radiation-inducible Egr-1 promoter. The goals of this study were to determine the safety and toxicity of TNFerade in combination with radiation therapy. Patients and Methods: TNFerade was administered by intratumoral administration, weekly for 6 weeks with concomitant radiation (30 to 70 Gy). Seven dose levels were studied (4 × 107 particle units [pu] to 4 × 1011 pu) in patients with solid tumors being treated with radiation. Results: Thirty-six patients were assessable for toxicity and 30 for tumor response. Most frequent TNFerade-related toxicities were fever (22%), injection site pain (19%), and chills (19%). No dose-limiting toxicities were observed. Overall, 21 of 30 patients (70%) demonstrated objective tumor response (five complete responses, nine partial responses, and seven minimal responses). In four of five patients with synchronous lesions, a differential response between lesions treated with TNFerade + radiation compared with radiation only was observed. Conclusion: This is the first human study with TNFerade and radiation. The integrated treatment was well tolerated in patients with predominantly prior treatment-refractory solid tumors. Controlled prospective clinical trials have been initiated to more fully define the therapeutic contribution of TNFerade.

AB - Purpose: TNFerade is a replication deficient adenovector that expresses human tumor necrosis factor alpha under control of the radiation-inducible Egr-1 promoter. The goals of this study were to determine the safety and toxicity of TNFerade in combination with radiation therapy. Patients and Methods: TNFerade was administered by intratumoral administration, weekly for 6 weeks with concomitant radiation (30 to 70 Gy). Seven dose levels were studied (4 × 107 particle units [pu] to 4 × 1011 pu) in patients with solid tumors being treated with radiation. Results: Thirty-six patients were assessable for toxicity and 30 for tumor response. Most frequent TNFerade-related toxicities were fever (22%), injection site pain (19%), and chills (19%). No dose-limiting toxicities were observed. Overall, 21 of 30 patients (70%) demonstrated objective tumor response (five complete responses, nine partial responses, and seven minimal responses). In four of five patients with synchronous lesions, a differential response between lesions treated with TNFerade + radiation compared with radiation only was observed. Conclusion: This is the first human study with TNFerade and radiation. The integrated treatment was well tolerated in patients with predominantly prior treatment-refractory solid tumors. Controlled prospective clinical trials have been initiated to more fully define the therapeutic contribution of TNFerade.

UR - http://www.scopus.com/inward/record.url?scp=1442332187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442332187&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.01.227

DO - 10.1200/JCO.2004.01.227

M3 - Article

C2 - 14726502

AN - SCOPUS:1442332187

VL - 22

SP - 592

EP - 601

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -